MEI Pharma (MEIP) Prices 17.5M Share Offering at $2.60/sh

MEI Pharma (MEIP) Announces Proposed 17.5M Share Public Offering of Common Stock

MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it plans to offer 17,500,000 shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the... More

MEI Pharma (MEIP) PT Raised to $11 at BTIG, Following Clinical Business Update

BTIG analyst Justin Zelin raised the price target on MEI Pharma (NASDAQ: MEIP) to $11.00 (from $9.00) while maintaining a Buy rating.

Pre-Open Stock Movers 11/30: (CPIX) (IMGN) (VIR) Higher; (JKS) (LIZI) (SEDG) Lower (more...)

Pre-Open Movers

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) 129% HIGHER; announced the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration. The non-narcotic pain reliever may now be administered just prior to surgery to enable patients to wake up from their procedure in significantly less pain.

ImmunoGen Inc. (Nasdaq: IMGN) 45.5% HIGHER; announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy... More

MEI Pharma’s (MEIP) zandelisib Has Best-in-Class Potential, Poised to Dominate the Space - Analyst

Earlier today, MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin announced that the pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies demonstrated a 70.3% objective response rate (ORR) as determined by Independent Review Committee (IRC) assessment in the primary efficacy population (n=91). In addition, 35.2% of patients achieved a complete... More

MEI Pharma (MEIP) Climbs 35% Following Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib

MEI Pharma (NASDAQ: MEIP) Climbs 35% Following Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib

MEI Pharma (MEIP) and Kyowa Kirin Reports Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and deliver novel medicines, today announced that the pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies demonstrated a 70.3% objective response rate (ORR) as determined by Independent Review Committee (IRC) assessment in the primary efficacy population (n=91). In addition, 35.2% of patients achieved a complete response. The data... More